Cargando…

Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON‐IDA/NEPHRO trials

Detalles Bibliográficos
Autores principales:	Wolf, Myles, Auerbach, Michael, Kalra, Philip A., Glaspy, John, Thomsen, Lars L., Bhandari, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756775/ https://www.ncbi.nlm.nih.gov/pubmed/33027541 http://dx.doi.org/10.1002/ajh.26015

Ejemplares similares

A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON‐EXT trial
por: Achebe, Maureen M., et al.
Publicado: (2020)

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
por: Bhandari, Sunil, et al.
Publicado: (2020)

A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial
por: Auerbach, Michael, et al.
Publicado: (2019)

Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery
por: Auerbach, Michael, et al.
Publicado: (2022)

Intravenous ferric derisomaltose for the treatment of iron deficiency anemia
por: Auerbach, Michael, et al.
Publicado: (2021)

A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose
por: Pollock, Richard F., et al.
Publicado: (2022)

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo
por: Brautaset Englund, Kristine V., et al.
Publicado: (2022)

Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial
por: Hansen, Rebecka, et al.
Publicado: (2022)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
por: Pollock, Richard F, et al.
Publicado: (2021)

A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status
por: Bhandari, S., et al.
Publicado: (2021)

Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
por: Kawabata, Hiroshi, et al.
Publicado: (2022)

Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
por: Emrich, I. E., et al.
Publicado: (2020)

Intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases: a single-arm, randomized, uncontrolled, open-label study
por: Kawabata, Hiroshi, et al.
Publicado: (2022)

Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
por: Kawabata, Hiroshi, et al.
Publicado: (2022)

A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2017)

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2018)

OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials
por: Wolf, Myles, et al.
Publicado: (2019)

Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial
por: Jose, Ambily, et al.
Publicado: (2019)

Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK
por: Sinclair, Rhona C. F., et al.
Publicado: (2022)

Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials
por: Naqash, Amreen, et al.
Publicado: (2018)

Neutropenia and Lymphocytopenia Among Arab Females with Iron Deficiency Anemia (IDA) and their Response to Iron therapy
por: Yassin, Mohamed A., et al.
Publicado: (2022)

Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
por: Argüelles-Arias, Federico, et al.
Publicado: (2022)

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
por: Kalra, Philip A, et al.
Publicado: (2016)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
por: Hofman, Jesse M. G., et al.
Publicado: (2018)

A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial
por: Birgegård, Gunnar, et al.
Publicado: (2016)

Is Nitric Oxide Nephro- or Cardioprotective?
por: Coutrot, Maxime, et al.
Publicado: (2019)

Frequency of iron deficiency anemia (IDA) among patients with Helicobacter pylori infection
por: Rahat, Adeel, et al.
Publicado: (2021)

Iron Sucrose Versus Oral Iron Therapy in Pregnancy Anemia
por: Neeru, Syal, et al.
Publicado: (2012)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis
por: Shin, Hye Won, et al.
Publicado: (2021)

Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia
por: Basha, Ahmad, et al.
Publicado: (2021)

Prevalence and Significance of Leukopenia Induced by Intravenous Iron Therapy in a Large Cohort of Females with Iron Deficiency Anemia (IDA)
por: Almasri, Hussam A, et al.
Publicado: (2022)

Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency
por: Calvet, Xavier, et al.
Publicado: (2012)

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
por: Rostoker, Guy, et al.
Publicado: (2022)

The Association between Iron-Deficiency Anemia (IDA) and Septic Arthritis (SA): The Real-World Data
por: Chiang, Cheng-Hung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_toqlqathl4r15pplopgq5ss1cn